Taro Pharmaceutical Industries Ltd. Securities Litigation

What happened

Taro Pharmaceutical Industries Ltd. and its executives allegedly made misleading statements about the company's business and prospects, causing the stock price to decline. Investors who purchased Taro common stock during the class period are entitled to recover damages from the settlement. The defendants deny all wrongdoing but have agreed to settle the litigation.

Do you qualify?

All persons who purchased Taro common stock on the open market on a United States stock exchange from July 2, 2014 through November 3, 2016, inclusive, and were damaged thereby. Excluded are defendants, their officers, directors, immediate family members, and certain related entities. Individual mutual fund investors do not qualify unless they personally purchased Taro stock during the class period.

What the settlement pays

Approximately $2.53 per allegedly damaged share, before deduction of attorneys' fees and expenses, Notice and Administration Expenses, and Taxes

Paid from a $36M settlement fund. Individual amounts depend on how many valid claims are filed.

Who is in the class

All Persons who purchased Taro common stock on the open market on a United States stock exchange from July 2, 2014 through November 3, 2016, both dates inclusive, and who were damaged thereby.

Quoted from the settlement notice.

How to file

Submit a completed Claim Form to the Claims Administrator by August 16, 2024 (deadline has passed). Claimants must provide proof of their stock purchases during the class period. Forms can be obtained from the settlement website. Contact JND Legal Administration at 855-208-4121 or info@TaroSecuritiesLitigation.com for assistance.